Pharmaceutical Drugs (Statins) Is The Largest Segment Driving The Growth Of Antihyperlipidemic Drugs Market

Antihyperlipidemic Drugs Market


The global Antihyperlipidemic Drugs Market is estimated to be valued at US$ 13.6 Bn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:


Antihyperlipidemic drugs or lipid-lowering drugs help in controlling high cholesterol and reducing triglyceride levels associated with conditions like atherosclerosis, cardiovascular diseases and stroke. These drugs lower lipid levels by inhibiting cholesterol synthesis in the liver or by acting as adsorbents to help remove cholesterol from the body.


Market key trends:


One of the key trends in the antihyperlipidemic drugs market is the rise in approvals of new drugs by regulatory bodies. In recent years, regulatory authorities like USFDA have approved new additions to antihyperlipidemic drugs owing to a rise in demand from patients and physicians. For instance, in May 2021, USFDA approved a new drug application filed by Amgen Inc. for Lumryza(ezetimibe), a cholesterol-lowering medication, in combination with diet and exercise, to treat high cholesterol or hyperlipidemia in children aged 10 to 17 years.

Market Trends


One of the key trends in the antihyperlipidemic drugs market is the rising prevalence of hyperlipidemia and cardiovascular diseases. Hyperlipidemia has become highly prevalent due to the increasing rates of obesity and unhealthy lifestyles. Cardiovascular diseases remain the leading cause of death globally. Therefore, the demand for drugs to lower cholesterol levels and triglycerides is growing significantly.


SWOT Analysis


Strengths: Drugs in this market such as statins are highly effective in lowering LDL cholesterol levels and reducing the risk of heart attacks and strokes. The market comprises several major pharmaceutical players with wide distribution networks.
Weaknesses: Statins have certain side effects such as muscle pain and are not suitable for all patients. Generic competition has eroded profits of major players.
Opportunities: Emerging markets offer significant growth potential due to increasing disease burden. New drug delivery technologies can improve treatment effectiveness and patient compliance.
Threats: Patent expiries of major drugs lead to decline in revenues of incumbent players. Stringent regulatory norms increase approval timelines for new formulations.


Key Takeaways


The Global Antihyperlipidemic Drugs Market Growth is expected to witness high growth, exhibiting CAGR of 7.5% over the forecast period, due to increasing prevalence of hyperlipidemia and cardiovascular diseases. According to WHO, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year.

The North America region dominates the antihyperlipidemic drugs market currently, owing to the rapid uptake of new drugs andgrowing obese population. However, the antihyperlipidemic drugs market in Asia Pacific region is expected to grow at a high CAGR due to improving healthcare infrastructure and increasing healthcare spending in the region.

Key players operating in the antihyperlipidemic drugs market are Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddyâ€TMs Laboratories Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company, Limited, among others. These companies are launching generic versions of blockbuster drugs and focusing on emerging markets for future growth.


Read More - https://www.insightprobing.com/antihyperlipidemic-drugs-market-share-size-demand-analysis-growth-and-trends-forecast/

Comments

Post a Comment

Popular posts from this blog

Riding the Wave: Navigating Dynamics in the Windsurf Foil Board Market

Image
   Windsurf Foil Board Market In the exhilarating world of water sports, the Windsurf Foil Board Market emerges as a key player, offering enthusiasts innovative equipment to enhance their riding experience. As this niche market continues to gain traction among windsurfing aficionados worldwide, it undergoes significant shifts influenced by various drivers, challenges, and geographical nuances. The Windsurf Foil Board Market size was valued at  US$ 167.4 Mn in 2024  and is expected to reach  US$ 268.6 Mn by 2031 , growing at a compound annual growth rate  (CAGR) of 7% from 2024 to 2031 Key Takeaways A prominent trend in the Windsurf Foil Board Market Demand is the increasing adoption of foil technology. Foil boards, equipped with hydrofoils beneath the waterline, enable riders to glide effortlessly above the water's surface, providing a thrilling and dynamic experience. This technological innovation has revolutionized the windsurfing landscape, attrac...
Read more

Idiopathic Hypersomnia Treatment Market is Anticipated to Witness High Growth Owing to Increasing Prevalence of Idiopathic Hypersomnia

Image
  Idiopathic Hypersomnia Treatment Market Idiopathic hypersomnia is a neurological sleep disorder characterized by excessive daytime sleepiness and long periods of sleep that does not improve even after long sleep. The treatment of idiopathic hypersomnia is done through medication and behavioral therapies. Medications like psychostimulants, serotonin modulators, wakefulness promoting agents are used to treat the condition and increase wakefulness. The increasing prevalence of idiopathic hypersomnia due to genetic and environmental factors is expected to drive the growth of the idiopathic hypersomnia treatment market. The Global Idiopathic Hypersomnia Treatment Market is estimated to be valued at US$ 389.86 Mn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 to 2030. Key Takeaways Key players operating in the Idiopathic Hypersomnia Treatment Market are Esaote SPA, Epica Animal Health, IDEXX Laboratories, Carestream Health, IMV Imaging, Fujifilm Hold...
Read more

Navigating Opportunities In The Niemann-Pick Disease Drug Type C Treatment Market

Image
  Niemann-Pick Disease Drug Type C Treatment Market Key Takeaways The Niemann-Pick Disease Drug Type C Treatment Market is witnessing significant growth, driven by advancements in medical research and a deeper understanding of the disease pathology. Niemann-Pick Disease Type C (NPC) is a rare genetic disorder characterized by the accumulation of cholesterol and other lipids within cells, leading to progressive neurological and visceral symptoms. With an increasing focus on rare diseases and orphan drug development, the market for NPC treatment is expanding rapidly, offering hope to patients and caregivers. Key players in the pharmaceutical industry are actively investing in research and development to bring novel therapies to market, underscoring the potential for transformative interventions in NPC management. Global Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at  US$ 45.40  million  in 2024, and is expected to exhibit a  CAG...
Read more